News and Trends 21 Feb 2023 Hemab Therapeutics receives $135M to address bleeding and thrombotic disorders …Maraganore, chair of Hemab’s board of directors. About HMB-001 HMB-001 is bispecific antibody that binds and stabilizes endogenous factor VIIa (FVIIa) with one antibody arm and TLT-1 on activated platelets… February 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2016 ‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease MorphoSys confirms that its antibody (bimagrumab) failed to meet the primary endpoint of a phase IIb/III trial for a muscle disease (sIBM), conducted by Novartis. Sad news for Novartis and… April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 Affibody and Chiesi Group to develop treatments for respiratory diseases …commercial milestone payments up to $637 million plus mid-single to low double-digit royalties on sales. About Affibody molecules Affibody molecules are a novel class of antibody mimetics with characteristics surpassing… March 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 May 2018 Here Are 10 of the Hottest Biotech Hubs in Europe …Planegg. Right there is one of Europe’s largest biotechs: MorphoSys, a billion-euro biotech that develops antibody therapies. The city is also home to Medigene, which develops T cell receptor technology… May 15, 2018 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2025 Von Willebrand disease: Star Therapeutics, Chugai and Band Therapeutics are breaking new ground …only the three main types but also additional subtypes,” said Rosenthal. Star Therapeutics and VGA039, the new wave in von Willebrand disease? “VGA039 is a first-in-class antibody therapy with a… January 9, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Human Immunology Biosciences launches with $120M …enhancements that come with our approach.” Clinical-stage assets HI-Bio’s clinical-stage assets include felzartamab, an anti-CD38 antibody, and HIB210, an anti-C5aR1 antibody. Felzartamab targets a protein expressed on the surface of… November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Feb 2023 10 biotech companies making a difference in rare diseases …Founded: 2019 Alchemab Therapeutics is a biotechnology company working on harnessing the power of the immune system to create the next generation of antibody therapeutics for hard-to-treat diseases that do… February 28, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 6 Mar 2023 The biggest private biotech investments in February 2023 …will be used to finance an ongoing phase 1/2 trial of a bispecific antibody treatment for the rare bleeding condition Glanzmann thrombasthenia in addition to the launch of a phase… March 6, 2023 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2020 Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal …deal’s terms, Affimed will receive €51M upfront to license to Roivant a preclinical-stage antibody drug for several undisclosed types of cancer. Roivant will handle the program once Affimed completes preclinical… November 16, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2022 Ethris Raises €23M to Make Inhaled Respiratory Therapies from mRNA …studies. However, commercializing treatments for viral infections like Covid-19 won’t be plain sailing. For example, Ethris and the Swiss antibody company Neurimmune discontinued the joint development of mRNA treatments encoding… February 1, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 26 May 2023 Could new Lyme disease tests help to prevent chronic infection? …order to create a better Lyme disease test. Dr Abdo Alnabulsi, chief executive officer (CEO) of EpitogenX, stated: “We are working on a serology based antibody test for the detection… May 26, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 10 Dec 2025 Promising cure for COPD: Is a breakthrough treatment within reach? …third new COPD therapy to gain approval in the U.S. in less than a year. Nucala is a monoclonal antibody that targets and binds to interleukin-5 (IL-5), a key messenger… December 10, 2025 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email